FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894563875> ?p ?o ?g. }

• W2894563875 endingPage "e023899" @default.
• W2894563875 startingPage "e023899" @default.
• W2894563875 abstract "Individualised treatment through therapeutic drug monitoring (TDM) may improve tuberculosis (TB) treatment outcomes but is not routinely implemented. Prospective clinical studies of drug exposure and minimum inhibitory concentrations (MICs) in multidrug-resistant TB (MDR-TB) are scarce. This translational study aims to characterise the area under the concentration-time curve of individual MDR-TB drugs, divided by the MIC for Mycobacterium tuberculosis isolates, to explore associations with markers of treatment progress and to develop useful strategies for clinical implementation of TDM in MDR-TB.Adult patients with pulmonary MDR-TB treated in Xiamen, China, are included. Plasma samples for measure of drug exposure are obtained at 0, 1, 2, 4, 6, 8 and 10 hours after drug intake at week 2 and at 0, 4 and 6 hours during weeks 4 and 8. Sputum samples for evaluating time to culture positivity and MIC determination are collected at days 0, 2 and 7 and at weeks 2, 4, 8 and 12 after treatment initiation. Disease severity are assessed with a clinical scoring tool (TBscore II) and quality of life evaluated using EQ-5D-5L. Drug concentrations of pyrazinamide, ethambutol, levofloxacin, moxifloxacin, cycloserine, prothionamide and para-aminosalicylate are measured by liquid chromatography tandem-mass spectrometry and the levels of amikacin measured by immunoassay. Dried blood spot on filter paper, to facilitate blood sampling for analysis of drug concentrations, is also evaluated. The MICs of the drugs listed above are determined using custom-made broth microdilution plates and MYCOTB plates with Middlebrook 7H9 media. MIC determination of pyrazinamide is performed in BACTEC MGIT 960.This study has been approved by the ethical review boards of Karolinska Institutet, Sweden and Fudan University, China. Informed written consent is given by participants. The study results will be submitted to a peer-reviewed journal.NCT02816931; Pre-results." @default.
• W2894563875 created "2018-10-12" @default.
• W2894563875 creator A5000820066 @default.
• W2894563875 creator A5004848467 @default.
• W2894563875 creator A5007224795 @default.
• W2894563875 creator A5013955124 @default.
• W2894563875 creator A5015236527 @default.
• W2894563875 creator A5017350057 @default.
• W2894563875 creator A5017537112 @default.
• W2894563875 creator A5024502790 @default.
• W2894563875 creator A5028072443 @default.
• W2894563875 creator A5028667300 @default.
• W2894563875 creator A5030569559 @default.
• W2894563875 creator A5031491320 @default.
• W2894563875 creator A5033089667 @default.
• W2894563875 creator A5036151138 @default.
• W2894563875 creator A5037967289 @default.
• W2894563875 creator A5045423164 @default.
• W2894563875 creator A5051162471 @default.
• W2894563875 creator A5066715433 @default.
• W2894563875 creator A5072929017 @default.
• W2894563875 creator A5081061481 @default.
• W2894563875 creator A5085060070 @default.
• W2894563875 date "2018-09-01" @default.
• W2894563875 modified "2023-10-16" @default.
• W2894563875 title "Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study" @default.
• W2894563875 cites W1837184534 @default.
• W2894563875 cites W1983163470 @default.
• W2894563875 cites W1987247410 @default.
• W2894563875 cites W1993133629 @default.
• W2894563875 cites W2002883043 @default.
• W2894563875 cites W2025330324 @default.
• W2894563875 cites W2060839842 @default.
• W2894563875 cites W2071699268 @default.
• W2894563875 cites W2097133372 @default.
• W2894563875 cites W2107834145 @default.
• W2894563875 cites W2113051108 @default.
• W2894563875 cites W2116105908 @default.
• W2894563875 cites W2124584779 @default.
• W2894563875 cites W2130403968 @default.
• W2894563875 cites W2130912795 @default.
• W2894563875 cites W2132963724 @default.
• W2894563875 cites W2133590486 @default.
• W2894563875 cites W2142944749 @default.
• W2894563875 cites W2145257685 @default.
• W2894563875 cites W2145484866 @default.
• W2894563875 cites W2146416369 @default.
• W2894563875 cites W2147213334 @default.
• W2894563875 cites W2149701134 @default.
• W2894563875 cites W2177680624 @default.
• W2894563875 cites W2285757988 @default.
• W2894563875 cites W2295478175 @default.
• W2894563875 cites W2401513239 @default.
• W2894563875 cites W2516938750 @default.
• W2894563875 cites W2556390964 @default.
• W2894563875 cites W2587471491 @default.
• W2894563875 cites W2606733530 @default.
• W2894563875 cites W2735459542 @default.
• W2894563875 cites W2773907647 @default.
• W2894563875 cites W3022423927 @default.
• W2894563875 doi "https://doi.org/10.1136/bmjopen-2018-023899" @default.
• W2894563875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6173237" @default.
• W2894563875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30287613" @default.
• W2894563875 hasPublicationYear "2018" @default.
• W2894563875 type Work @default.
• W2894563875 sameAs 2894563875 @default.
• W2894563875 citedByCount "7" @default.
• W2894563875 countsByYear W28945638752019 @default.
• W2894563875 countsByYear W28945638752020 @default.
• W2894563875 countsByYear W28945638752021 @default.
• W2894563875 crossrefType "journal-article" @default.
• W2894563875 hasAuthorship W2894563875A5000820066 @default.
• W2894563875 hasAuthorship W2894563875A5004848467 @default.
• W2894563875 hasAuthorship W2894563875A5007224795 @default.
• W2894563875 hasAuthorship W2894563875A5013955124 @default.
• W2894563875 hasAuthorship W2894563875A5015236527 @default.
• W2894563875 hasAuthorship W2894563875A5017350057 @default.
• W2894563875 hasAuthorship W2894563875A5017537112 @default.
• W2894563875 hasAuthorship W2894563875A5024502790 @default.
• W2894563875 hasAuthorship W2894563875A5028072443 @default.
• W2894563875 hasAuthorship W2894563875A5028667300 @default.
• W2894563875 hasAuthorship W2894563875A5030569559 @default.
• W2894563875 hasAuthorship W2894563875A5031491320 @default.
• W2894563875 hasAuthorship W2894563875A5033089667 @default.
• W2894563875 hasAuthorship W2894563875A5036151138 @default.
• W2894563875 hasAuthorship W2894563875A5037967289 @default.
• W2894563875 hasAuthorship W2894563875A5045423164 @default.
• W2894563875 hasAuthorship W2894563875A5051162471 @default.
• W2894563875 hasAuthorship W2894563875A5066715433 @default.
• W2894563875 hasAuthorship W2894563875A5072929017 @default.
• W2894563875 hasAuthorship W2894563875A5081061481 @default.
• W2894563875 hasAuthorship W2894563875A5085060070 @default.
• W2894563875 hasBestOaLocation W28945638751 @default.
• W2894563875 hasConcept C112705442 @default.
• W2894563875 hasConcept C114851261 @default.
• W2894563875 hasConcept C126322002 @default.
• W2894563875 hasConcept C142724271 @default.
• W2894563875 hasConcept C2776228421 @default.

• next